Hermans Kate

DirectorAmbrx Biopharma Inc. (AMAM) · full profile →Form 4 · filed Jan 31, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
0 non-derivative · 6 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 27, 2023Grant(A)210K210K
Jan 27, 2023Disposed to issuer(D)210K0
Jan 27, 2023Disposed to issuer(D)210K0
Jan 27, 2023Grant(A)210K210K
Jan 27, 2023Disposed to issuer(D)105K0
Jan 27, 2023Grant(A)105K105K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-005788) within minutes of acceptance. Every field above traces to the original document. Verify it directly: